Orostat 8%

Epinephrine Hydrochloride


Gingi-pak A Division Of The Belport
Human Otc Drug
NDC 10129-006
Orostat 8% also known as Epinephrine Hydrochloride is a human otc drug labeled by 'Gingi-pak A Division Of The Belport'. National Drug Code (NDC) number for Orostat 8% is 10129-006. This drug is available in dosage form of Solution. The names of the active, medicinal ingredients in Orostat 8% drug includes Epinephrine Hydrochloride - 1200 mg/15mL . The currest status of Orostat 8% drug is Active.

Drug Information:

Drug NDC: 10129-006
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Orostat 8%
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Epinephrine Hydrochloride
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Gingi-pak A Division Of The Belport
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Solution
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:EPINEPHRINE HYDROCHLORIDE - 1200 mg/15mL
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:DENTAL
PERIODONTAL
SUBGINGIVAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: UNAPPROVED DRUG OTHER
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 04 Apr, 1990
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 04 May, 2026
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Gingi-Pak a Division of the Belport
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UNII:WBB047OO38
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class:Adrenergic alpha-Agonists [MoA]
Adrenergic beta-Agonists [MoA]
Catecholamine [EPC]
Catecholamines [CS]
alpha-Adrenergic Agonist [EPC]
beta-Adrenergic Agonist [EPC]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
10129-006-0215 mL in 1 BOTTLE, GLASS (10129-006-02)04 Apr, 1990N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Purpose purpose

Product Elements:

Orostat 8% epinephrine hydrochloride epinephrine hydrochloride epinephrine sodium dithionite sodium thiosulfate sodium phosphate, monobasic, anhydrous sodium chloride propylparaben benzyl alcohol edetic acid methylparaben

Indications and Usage:

Uses uses

Warnings:

Warnings warnings

Dosage and Administration:

Directions directions

Stop Use:

Do not use do not use

Description:

Description description

Package Label Principal Display Panel:

Principal display-orostat 8% principal display-orostat 8%


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.